These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37329712)

  • 1. Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.
    Yang C; Chen Y; Wu T; Gao Y; Liu X; Yang Y; Ling Y; Jia Y; Deng M; Wang J; Zhou Y
    Eur J Med Chem; 2023 Oct; 258():115543. PubMed ID: 37329712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insilco and Invitro approaches identify novel dual PI3K/AKT pathway inhibitors to control acute myeloid leukemia cell proliferations.
    Abohassan M; Alshahrani M; Alshahrani MY; Rajagopalan P
    Med Oncol; 2022 Oct; 39(12):249. PubMed ID: 36209300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis.
    Tseng CY; Fu YH; Ou DL; Lu JW; Hou HA; Lin LI
    Cancer Gene Ther; 2023 Dec; 30(12):1691-1701. PubMed ID: 37821641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.
    Deng L; Jiang L; Lin XH; Tseng KF; Liu Y; Zhang X; Dong RH; Lu ZG; Wang XJ
    Acta Pharmacol Sin; 2017 Mar; 38(3):382-391. PubMed ID: 28042875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors.
    Li C; Han Y; Wang Z; Yu Y; Wang C; Ren Z; Guo Y; Zhu T; Li X; Dong S; Ma M
    Eur J Med Chem; 2023 Feb; 247():115030. PubMed ID: 36586298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
    Zhang J; Lv X; Ma X; Hu Y
    Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X; Zhang B; Luo L; Yang Y; He B; Zhang Q; Wang L; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pyridinesulfonamide derivative FD268 suppresses cell proliferation and induces apoptosis via inhibiting PI3K pathway in acute myeloid leukemia.
    Chen Y; Wu T; Yang C; Lu M; Chen Z; Deng M; Jia Y; Yang Y; Liu X; Wang H; Ling Y; Lu L; Zhou Y
    PLoS One; 2022; 17(11):e0277893. PubMed ID: 36413544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1
    Yang J; Liu Y; Lan S; Yu S; Ma X; Luo D; Shan H; Zhong X; Yan G; Li R
    J Med Chem; 2022 Oct; 65(19):12781-12801. PubMed ID: 36191148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y; Sun X; Luo L; Peng R; Yang R; Cheng Z; Lv Y; Li H; Tang Q; Zhu W; Qiao D; Xu S
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
    Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (
    Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
    J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
    Zhang B; Zhang Q; Xiao Z; Sun X; Yang Z; Gu Q; Liu Z; Xie T; Jin Q; Zheng P; Xu S; Zhu W
    Bioorg Chem; 2020 Jan; 95():103525. PubMed ID: 31887474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.
    Xiang HY; Wang X; Chen YH; Zhang X; Tan C; Wang Y; Su Y; Gao ZW; Chen XY; Xiong B; Gao ZB; Chen Y; Ding J; Meng LH; Yang CH
    Eur J Med Chem; 2021 Jan; 209():112913. PubMed ID: 33109399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
    Herschbein L; Liesveld JL
    Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.